For example, in 2020 when this study was initiated, dabrafenib was approved in Canada for adult patients with melanoma and non‐small cell lung cancer but not approved for patients with BRAF V600E‐mutated gliomas or Langerhans cell histiocytosis (LCH), despite demonstrated improvement of patients' outcomes.7 The gene discussed is BRAF; the disease is Langerhans cell histiocytosis.